Imbruvica (ibrutinib) — Medica

Initial criteria

• Patient is age ≥ 18 years
• Patient is not a candidate for or intolerant to high-dose methotrexate OR patient has tried at least one therapy (e.g., methotrexate, rituximab, vincristine, procarbazine, cytarabine, thiotepa, carmustine, intrathecal methotrexate, cytarabine, rituximab)

Reauthorization criteria

• Patient continues to meet initial criteria

Approval duration

1 year